Stay away : Ranbaxy Lab, till it prooves no guilty

Thebullishtrends: Avoid for some time Ranbaxy Lab, the India’s largest pharma company in terms of
sales.

Market players are stay away to Ranbaxy by following the reportsthe US government has levelled serious allegations against the company. The US department of justice (DoJ) has announced that there was evidence to suggest that Ranbaxy used active pharmaceutical ingredients (API) from unapproved sources, blended unapproved API with approved API, and used less-than-approved API at its Paonta Sahib (Himachal Pradesh) plant in its drugs, resulting in the sale of subpotent, super- potent or adulterated medicines in the US. It is better to avoid this stock for some time to proove that it has not comitted any fraud.